Wellnex bumps first $3M payment for Pain Away into 1Q25 – when it lists in London

The Market Herald
05 Nov 2024

Wellnex Life Ltd (ASX:WNX) has unveiled its plans to defer a $2.95M payment to 360 Health until it lists on the London exchange in January.

Following its acquisition of topical pain relief product brand Pain Way, the cannabis-focused healthcare stock has now inked a deal with vendors 365 Health.

In stead of paying $2.95M in late October, it’s deferred that payment through to 20 January 2025. This Wellnex intends to align with its planned listing on the London Stock Exchange.

The move echoes, somewhat, that of Telix (ASX:TLX) earlier this year which intended to list on the NASDAQ, got most of the way there, then pulled its plans to do so.

Hopefully Wellnex can have more luck. It’s set to publish a prospectus for the LSE later this month.

The company reiterated its rationale on Tuesday:

“Listing on the LSE Main Board is being pursued to aid the Company’s retirement of all debts, including the deferred consideration and convertible notes, accelerate our international expansion and be able to access UK based institutional and sophisticated investors.”

In between the lines – the company needs more liquidity. It’s more or less hinging on the LSE listing to pay its consideration to 365 Health – it finished the September quarter with $300,000 in cash.

WNX last traded at 66.5cps.

Join the discussion: See what HotCopper users are saying about Wellnex Life and be part of the conversations that move the markets.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10